NYSE · CIK 0001894525
APUS Apimeds Pharmaceuticals US, Inc.
Insider trading from SEC Form 4. Last filing Nov 21, 2025. Close $5.02 on Oct 9, 2026, +214% from the 52-week low and -87% from the high.
In brief
Apimeds Pharmaceuticals US, Inc. (APUS) has 24 SEC Form 4 filings on file from 8 insiders, the latest filed on Nov 21, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at APUS. The newest: Christopher Kim (Chairman and CMO) bought $50k of stock on May 13, 2025, filed May 15, 2025, scored 50 (moderate). The largest of the 3 shown: Inscobee Inc. (10% owner) bought $2.0M on May 12, 2025, scored 53 (moderate). 3 insiders bought within 14 days of each other around May 13, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Apimeds Pharmaceuticals US, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Christopher Kim Chairman and CMO buy | $50k 27,500 shares | - | - | |
| 53Moderate | Inscobee Inc. owner buy | $2.0M 500,000 shares | +34% | - | |
| 37Weak | Jakap Koo director buy | $57k 28,500 shares | +5% | - |
Transactions
Every row filed, 34 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Elona Kogan director | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 13, 2025 |
| Nov 11, 2025 | Bennett Weintraub director | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 13, 2025 |
| Nov 11, 2025 | Hankil Yoon director | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 13, 2025 |
| Nov 11, 2025 | Jakap Koo director | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 13, 2025 |
| Nov 11, 2025 | Carol A O'Donnell director | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 13, 2025 |
| Oct 15, 2025 | Elona Kogan director | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 24, 2025 |
| Oct 15, 2025 | Carol A O'Donnell director | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 21, 2025 |
| Oct 15, 2025 | Erik C. Emerson Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +215,000 | $0.00 | $0 | 215,000 | Oct 17, 2025 |
| Oct 15, 2025 | Christopher Kim Chairman and CMO | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 17, 2025 |
| Oct 15, 2025 | Bennett Weintraub director | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 17, 2025 |
| Oct 15, 2025 | Hankil Yoon director | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 17, 2025 |
| Oct 15, 2025 | Jakap Koo director | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 17, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Common Stock, par value $0.01 per share | +71,090 | $2.60 | $185k | 2,055,706 | Jun 11, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Common Stock, par value $0.01 per share | +44,041 | $2.60 | $115k | 2,099,747 | Jun 11, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Convertible Promissory Notederivative | - | $0.00 | - | 0 | Jun 11, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Convertible Promissory Notederivative | - | $0.00 | - | 0 | Jun 11, 2025 |
| May 16, 2025 | Elona Kogan director | AGrant or award Stock Option (right to buy)derivative | +5,780 | $0.00 | $0 | 5,780 | May 20, 2025 |
| May 16, 2025 | Erik C. Emerson Chief Executive Officer | AGrant or award Common Stock, par value $0.01 per share | +750,000 | $0.00 | $0 | 750,000 | May 20, 2025 |
| May 16, 2025 | Christopher Kim Chairman and CMO | AGrant or award Common Stock, par value $0.01 per share | +250,000 | $0.00 | $0 | 277,500 | May 20, 2025 |
| May 16, 2025 | Carol A O'Donnell director | AGrant or award Stock Option (right to buy)derivative | +5,780 | $0.00 | $0 | 5,780 | May 20, 2025 |
| May 16, 2025 | Jakap Koo director | AGrant or award Stock Option (right to buy)derivative | +5,780 | $0.00 | $0 | 5,780 | May 20, 2025 |
| May 16, 2025 | Bennett Weintraub director | AGrant or award Stock Option (right to buy)derivative | +5,780 | $0.00 | $0 | 5,780 | May 20, 2025 |
| May 16, 2025 | Hankil Yoon director | AGrant or award Stock Option (right to buy)derivative | +5,780 | $0.00 | $0 | 5,780 | May 20, 2025 |
| May 16, 2025 | Erik C. Emerson Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +347,279 | $0.00 | $0 | 347,279 | May 20, 2025 |
| May 13, 2025 | Christopher Kim Chairman and CMO | POpen-market purchase Common Stock, par value $0.01 per share | +19,770 | $1.82 | $36k | 19,770 | May 15, 2025 |
| May 14, 2025 | Christopher Kim Chairman and CMO | POpen-market purchase Common Stock, par value $0.01 per share | +7,730 | $1.86 | $14k | 27,500 | May 15, 2025 |
| May 12, 2025 | Inscobee Inc. owner | POpen-market purchase Common Stock, par value $0.01 per share | +500,000 | $4.00 | $2.0M | 1,984,616 | May 14, 2025 |
| May 12, 2025 | Jakap Koo director | POpen-market purchase Common Stock, par value $0.01 per share | +28,500 | $1.99 | $57k | 643,885 | May 14, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Common Stock, par value $0.01 per shareindirect: By Apimeds Inc. | +182,002 | $2.60 | $473k | 4,316,618 | May 14, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Common Stock, par value $0.01 per shareindirect: By Apimeds Inc. | +71,090 | $2.60 | $185k | 4,387,708 | May 14, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Common Stock, par value $0.01 per share | +44,041 | $2.60 | $115k | 2,028,657 | May 14, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Convertible Promissory Notederivativeindirect: By Apimeds Inc. | - | $0.00 | - | 0 | May 14, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Convertible Promissory Notederivativeindirect: By Apimeds Inc. | - | $0.00 | - | 0 | May 14, 2025 |
| May 12, 2025 | Inscobee Inc. owner | CConversion Convertible Promissory Notederivative | - | $0.00 | - | 0 | May 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Erik C. EmersonChief Executive Officer
- Inscobee Inc.owner
- Christopher KimChairman and CMO
- Elona Kogandirector
- Jakap Koodirector
- Carol A O'Donnelldirector
- Bennett Weintraubdirector
- Hankil Yoondirector
Questions about APUS
Answered from the filings on this page, as of the latest one.
Are insiders buying APUS?
No. In the last 90 days no insider at Apimeds Pharmaceuticals US, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade APUS on the open market?
Christopher Kim (Chairman and CMO) bought $50k of APUS on May 13, 2025 and filed the Form 4 on May 15, 2025. InsiderTell scored 50 (moderate), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Apimeds Pharmaceuticals US, Inc.?
8 people have filed a Form 4 at Apimeds Pharmaceuticals US, Inc., among them Erik C. Emerson (Chief Executive Officer), Inscobee Inc. (10% owner), Christopher Kim (Chairman and CMO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.